JP2010043089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010043089A5 JP2010043089A5 JP2009211917A JP2009211917A JP2010043089A5 JP 2010043089 A5 JP2010043089 A5 JP 2010043089A5 JP 2009211917 A JP2009211917 A JP 2009211917A JP 2009211917 A JP2009211917 A JP 2009211917A JP 2010043089 A5 JP2010043089 A5 JP 2010043089A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hngf
- human
- agent
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 15
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 15
- 101150111783 NTRK1 gene Proteins 0.000 claims description 12
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 7
- 208000004454 Hyperalgesia Diseases 0.000 claims description 6
- 208000035154 Hyperesthesia Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 15
- 208000027866 inflammatory disease Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000002193 Pain Diseases 0.000 claims 10
- 206010003246 arthritis Diseases 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 201000004681 Psoriasis Diseases 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 206010025135 lupus erythematosus Diseases 0.000 claims 5
- 201000006417 multiple sclerosis Diseases 0.000 claims 5
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 206010012442 Dermatitis contact Diseases 0.000 claims 4
- 208000007514 Herpes zoster Diseases 0.000 claims 4
- 101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 claims 4
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 claims 4
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 206010009887 colitis Diseases 0.000 claims 4
- 208000010247 contact dermatitis Diseases 0.000 claims 4
- 201000003146 cystitis Diseases 0.000 claims 4
- 102000052073 human NGFR Human genes 0.000 claims 4
- 210000000987 immune system Anatomy 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 101100404651 Mus musculus Ngf gene Proteins 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 102000046917 human NGF Human genes 0.000 claims 2
- 102000057041 human TNF Human genes 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 108091008604 NGF receptors Proteins 0.000 claims 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 5
- 230000003993 interaction Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29439201P | 2001-05-30 | 2001-05-30 | |
| US60/294,392 | 2001-05-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592967A Division JP4567944B2 (ja) | 2001-05-30 | 2002-05-09 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013025893A Division JP2013139453A (ja) | 2001-05-30 | 2013-02-13 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010043089A JP2010043089A (ja) | 2010-02-25 |
| JP2010043089A5 true JP2010043089A5 (enExample) | 2012-10-25 |
| JP5761902B2 JP5761902B2 (ja) | 2015-08-12 |
Family
ID=23133215
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592967A Expired - Lifetime JP4567944B2 (ja) | 2001-05-30 | 2002-05-09 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2009211917A Expired - Lifetime JP5761902B2 (ja) | 2001-05-30 | 2009-09-14 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2013025893A Withdrawn JP2013139453A (ja) | 2001-05-30 | 2013-02-13 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2014215231A Pending JP2015061840A (ja) | 2001-05-30 | 2014-10-22 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2016079748A Expired - Lifetime JP6271631B2 (ja) | 2001-05-30 | 2016-04-12 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592967A Expired - Lifetime JP4567944B2 (ja) | 2001-05-30 | 2002-05-09 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013025893A Withdrawn JP2013139453A (ja) | 2001-05-30 | 2013-02-13 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2014215231A Pending JP2015061840A (ja) | 2001-05-30 | 2014-10-22 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2016079748A Expired - Lifetime JP6271631B2 (ja) | 2001-05-30 | 2016-04-12 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (7) | US7727527B2 (enExample) |
| EP (2) | EP2340849A1 (enExample) |
| JP (5) | JP4567944B2 (enExample) |
| KR (3) | KR101004353B1 (enExample) |
| CN (2) | CN101653604A (enExample) |
| AT (1) | ATE522229T1 (enExample) |
| AU (7) | AU2002308722B2 (enExample) |
| BR (1) | BR0210231A (enExample) |
| CA (2) | CA2975521A1 (enExample) |
| CY (1) | CY1112425T1 (enExample) |
| DK (1) | DK1401498T3 (enExample) |
| ES (1) | ES2371748T3 (enExample) |
| IL (2) | IL158921A0 (enExample) |
| MX (1) | MXPA03010911A (enExample) |
| NZ (2) | NZ529612A (enExample) |
| PT (1) | PT1401498E (enExample) |
| WO (1) | WO2002096458A1 (enExample) |
| ZA (1) | ZA200308999B (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2340849A1 (en) * | 2001-05-30 | 2011-07-06 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| EP1556083B1 (en) | 2002-10-08 | 2011-02-02 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same |
| EP2270048B1 (en) | 2002-12-24 | 2015-11-11 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| AU2011201157C1 (en) * | 2002-12-24 | 2017-09-07 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| KR20050111598A (ko) * | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| KR100894191B1 (ko) | 2003-07-15 | 2009-04-22 | 암젠 인코포레이티드 | 선택적인 ｎｇｆ 경로 저해제로서의 인체 항-ｎｇｆ 중화 항체 및 이 항체를 포함하는 약학적 조성물 |
| MEP31508A (hr) * | 2003-07-15 | 2010-10-10 | Amgen Inc | Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| AU2005243247B2 (en) * | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| EP2298345A3 (en) | 2005-01-24 | 2012-03-21 | MedImmune Limited | Specific binding members for NGF |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| EP1857146A1 (en) * | 2006-05-16 | 2007-11-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Treatment of respiratory disorders |
| NZ579010A (en) | 2007-02-20 | 2012-03-30 | Anaptysbio Inc | Somatic hypermutation systems |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| MY161564A (en) * | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| WO2009077993A2 (en) * | 2007-12-17 | 2009-06-25 | Pfizer Limited | Treatment of interstitial cystitis |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PE20100054A1 (es) | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
| MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| HRP20140309T1 (hr) | 2008-10-22 | 2014-05-09 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE |
| MX2011011670A (es) * | 2009-05-01 | 2011-11-18 | Abbott Lab | Inmunoglobulinas de dominio variable dual y usos de las mismas. |
| KR20120088550A (ko) | 2009-05-04 | 2012-08-08 | 애보트 리서치 비.브이. | 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| AR078254A1 (es) * | 2009-09-01 | 2011-10-26 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| MX2012004415A (es) * | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2547365A1 (en) | 2010-03-17 | 2013-01-23 | Abbott Research B.V. | Anti-nerve growth factor (ngf) antibody compositions |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| AU2015258217A1 (en) * | 2010-08-19 | 2015-12-03 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| PH12013500337A1 (en) | 2010-08-26 | 2017-08-23 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| NZ611076A (en) * | 2010-12-01 | 2015-09-25 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| ITRM20110024A1 (it) * | 2011-01-24 | 2012-07-25 | Consiglio Nazionale Ricerche | Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche. |
| JP5376095B2 (ja) | 2011-08-11 | 2013-12-25 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
| US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
| US9120870B2 (en) | 2011-12-30 | 2015-09-01 | Abbvie Inc. | Dual specific binding proteins directed against IL-13 and IL-17 |
| JP6629069B2 (ja) * | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | イヌ化抗ｎｇｆ抗体およびその方法 |
| AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| EP2970459A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
| WO2015114150A1 (en) | 2014-02-02 | 2015-08-06 | Medimmune Limited | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
| JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形 |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| KR102566858B1 (ko) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US20180357486A1 (en) * | 2017-06-07 | 2018-12-13 | Satori Worldwide, Llc | System and method for analyzing video frames in a messaging system |
| MX2020009526A (es) | 2018-03-12 | 2020-10-28 | Zoetis Services Llc | Anticuerpos anti-ngf y metodos de estos. |
| CN108743568B (zh) * | 2018-06-05 | 2021-09-07 | 桂林医学院附属医院 | 用于降低气道高反应性的抗ngf抗体缓释微球及制备方法 |
| CN112625128B (zh) * | 2020-08-06 | 2022-11-08 | 熙源安健医药（上海）有限公司 | 抗ngf抗体及其抗原结合片段、其制备方法和应用 |
| CN117279942A (zh) | 2020-09-28 | 2023-12-22 | 免疫医疗有限公司 | 用于治疗疼痛的化合物和方法 |
| CA3254914A1 (en) | 2020-10-07 | 2026-03-02 | Zoetis Services Llc | Anti-ngf antibodies and methods of use thereof |
| WO2022166956A1 (en) * | 2021-02-02 | 2022-08-11 | Nanjing Nutrabuilding Bio-Tech Co., Ltd. | Bhb liposomes and preparation methods thereof |
| WO2023111157A1 (en) | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized and felinized antibodies to human ngf |
| US20230348608A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score |
| AU2024238259A1 (en) | 2023-03-17 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for osteoarthritis (oa) |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
| WO2026054762A1 (en) | 2024-09-05 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for adjudicated arthropathy (aa) |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JPH06503722A (ja) * | 1990-11-30 | 1994-04-28 | アボット・ラボラトリーズ | 末端欠失神経成長因子受容体の検出に有用なイムノアッセイおよびモノクローナル抗体 |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
| EP1004312A1 (en) * | 1993-07-30 | 2000-05-31 | Kennedy Institute Of Rheumatology | Method for treating multiple sclerosis |
| US5753225A (en) * | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
| US5728803A (en) * | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| IT1306704B1 (it) * | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| US7220840B2 (en) * | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| JP4340062B2 (ja) * | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| EP2340849A1 (en) * | 2001-05-30 | 2011-07-06 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
| CA2500901A1 (en) * | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| KR20050111598A (ko) * | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| AU2005243247B2 (en) * | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
-
2002
- 2002-05-09 EP EP10010557A patent/EP2340849A1/en not_active Ceased
- 2002-05-09 AT AT02774103T patent/ATE522229T1/de active
- 2002-05-09 CN CN200910171008A patent/CN101653604A/zh active Pending
- 2002-05-09 US US10/479,872 patent/US7727527B2/en not_active Expired - Lifetime
- 2002-05-09 PT PT02774103T patent/PT1401498E/pt unknown
- 2002-05-09 ES ES02774103T patent/ES2371748T3/es not_active Expired - Lifetime
- 2002-05-09 BR BR0210231-5A patent/BR0210231A/pt not_active Application Discontinuation
- 2002-05-09 CN CNA028149920A patent/CN1684708A/zh active Pending
- 2002-05-09 MX MXPA03010911A patent/MXPA03010911A/es not_active Application Discontinuation
- 2002-05-09 CA CA2975521A patent/CA2975521A1/en not_active Abandoned
- 2002-05-09 AU AU2002308722A patent/AU2002308722B2/en not_active Expired
- 2002-05-09 EP EP02774103A patent/EP1401498B1/en not_active Revoked
- 2002-05-09 KR KR1020087027819A patent/KR101004353B1/ko not_active Expired - Lifetime
- 2002-05-09 KR KR1020107027004A patent/KR20100132559A/ko not_active Withdrawn
- 2002-05-09 CA CA2448956A patent/CA2448956C/en not_active Expired - Lifetime
- 2002-05-09 NZ NZ529612A patent/NZ529612A/xx not_active IP Right Cessation
- 2002-05-09 JP JP2002592967A patent/JP4567944B2/ja not_active Expired - Lifetime
- 2002-05-09 WO PCT/US2002/015284 patent/WO2002096458A1/en not_active Ceased
- 2002-05-09 KR KR10-2003-7015659A patent/KR20040049829A/ko not_active Ceased
- 2002-05-09 DK DK02774103.2T patent/DK1401498T3/da active
- 2002-05-09 IL IL15892102A patent/IL158921A0/xx unknown
- 2002-05-09 NZ NZ544410A patent/NZ544410A/en not_active IP Right Cessation
-
2003
- 2003-11-18 IL IL158921A patent/IL158921A/en active IP Right Grant
- 2003-11-19 ZA ZA2003/08999A patent/ZA200308999B/en unknown
-
2007
- 2007-08-16 AU AU2007207881A patent/AU2007207881B2/en not_active Expired
-
2009
- 2009-09-14 JP JP2009211917A patent/JP5761902B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-15 AU AU2010200170A patent/AU2010200170B2/en not_active Expired
- 2010-04-06 US US12/755,279 patent/US20100254990A1/en not_active Abandoned
-
2011
- 2011-04-19 US US13/090,048 patent/US20110268725A1/en not_active Abandoned
- 2011-11-28 CY CY20111101167T patent/CY1112425T1/el unknown
-
2012
- 2012-09-06 US US13/605,722 patent/US20130004495A1/en not_active Abandoned
-
2013
- 2013-02-13 JP JP2013025893A patent/JP2013139453A/ja not_active Withdrawn
- 2013-10-10 AU AU2013242812A patent/AU2013242812A1/en not_active Abandoned
-
2014
- 2014-03-24 US US14/223,881 patent/US20140294829A1/en not_active Abandoned
- 2014-10-22 JP JP2014215231A patent/JP2015061840A/ja active Pending
-
2016
- 2016-04-12 JP JP2016079748A patent/JP6271631B2/ja not_active Expired - Lifetime
- 2016-04-12 US US15/097,225 patent/US20170066819A1/en not_active Abandoned
- 2016-11-03 AU AU2016253605A patent/AU2016253605A1/en not_active Abandoned
-
2018
- 2018-06-04 AU AU2018203920A patent/AU2018203920A1/en not_active Abandoned
-
2020
- 2020-05-11 US US16/871,525 patent/US20200399357A1/en not_active Abandoned
- 2020-05-12 AU AU2020203115A patent/AU2020203115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536072A5 (enExample) | ||
| JP5537740B2 (ja) | Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 | |
| JP7736667B2 (ja) | Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 | |
| US11673962B2 (en) | Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab | |
| JP2021193121A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| CN105392803B (zh) | C5aR拮抗剂的用途 | |
| CN112969719A (zh) | 双功能融合蛋白及其医药用途 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| CA3207818A1 (en) | Anti-tl1a antibody compositions and methods of treatment in the lung | |
| KR20140015139A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20130100118A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20130133247A (ko) | Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| CN103189074A (zh) | 使用il-17拮抗剂治疗类风湿性关节炎的方法 | |
| JP2023520676A (ja) | Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 | |
| AU2018369986A1 (en) | Treating Hidradenitis suppurativa with IL-17 antagonists | |
| JP2019515676A5 (enExample) | ||
| CA3207817A1 (en) | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof | |
| JP2021119168A (ja) | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 | |
| JP7572041B2 (ja) | 重症喘息を処置するための組成物および方法 | |
| JP6663910B2 (ja) | 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法 | |
| US12144859B2 (en) | B cell depleting agent for the treatment of atherosclerosis | |
| JP2026507534A (ja) | 抗ｔｌ１ａ抗体組成物及び皮膚の治療方法 | |
| JP2021500895A5 (enExample) |